Veraflox is a next-generation treatment for bacterial skin infections that targets two key enzymes necessary for bacterial DNA replication.

Treatment of acute infections of the upper respiratory tract caused by susceptible strains of Pasteurella multocida, Escherichia coli and the Staphylococcus intermedius group (including S. pseudintermedius).